CORONA Remedies Limited has informed the Exchange regarding Change in Auditors of the company.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies reported strong FY2026 results: standalone revenue grew 17.3% to Rs. 1,403.18 Crores and net profit rose 24% to Rs. 184.85 Crores, with an unmodified audit opinion from Deloitte Haskins & Sells. The Board recommended a 100% dividend (Rs. 10 per share), payable by August 7, 2026, to shareholders on record June 19, 2026. Key leadership changes include appointment of Walker Chandiok & Co LLP as the incoming statutory auditor for five years (FY2026-27 to FY2030-31), replacing Deloitte whose current term concludes with this audit cycle. Dr. Kirtikumar Mehta was recommended for re-appointment as Non-Executive Chairman for another five years. The company listed on NSE/BSE in December 2025 via an IPO. An exceptional charge of Rs. 19.10 Crores was recorded due to the new Labour Codes.
Strong operational performance with revenue and profit growth supports the stock. The planned auditor transition to Walker Chandiok is routine (not a mid-term resignation) and poses no governance concern. Dividend payout is positive for income-seeking investors.